PAREXEL Wins 2014 IABC Gold Quill Merit Award for Internal Communications
International recognition for driving business performance through effective employee engagement
BOSTON, MA, June 19, 2014 – PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that it has won a 2014 Gold Quill Merit Award from the International Association of Business Communicators (IABC). The award recognizes achievement in driving business performance and employee engagement through successful communication planning and execution. IABC is a global network of more than 14,000 professionals in 70 countries committed to improving organizational effectiveness through strategic communication.
“PAREXEL recognizes that a highly engaged workforce is essential for fulfilling our mission of helping our customers prevent and cure disease,” said Diana Martin, Vice President of Corporate Communications, PAREXEL. “As a result, we’ve made internal communications a high priority. Winning a Gold Quill Award is a prestigious recognition of our customer-focused approach to employee engagement.”
In February 2014, PAREXEL launched a new corporate branding initiative that highlights the Company’s proven approach to help simplify the drug development journey for clients. Concurrently, the Company renewed its internal focus on fostering a performance-driven, customer-centric culture across the organization.
“The PAREXEL brand is a reflection of the dedicated people behind it,” said Christopher Tama, Worldwide Head of Marketing, PAREXEL. “Our communications help enhance our customer focus by further unifying us as a company. As a result, we are better able to work together as one PAREXEL to fulfill our continued commitment to customers: “Your Journey. Our Mission.™”
For more than 40 years, IABC’s Gold Quill Awards have recognized excellence in strategic communications worldwide. Sponsored by Towers Watson, it is the only international awards program for business communications. The competitive program attracts nominations from companies in diverse industries. Winners are selected for leading initiatives that address corporate and audience needs and make a meaningful business impact.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 75 locations in 50 countries around the world, and has approximately 15,335 employees. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and “Your Journey. Our Mission.” are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions, and to integrate newly acquired businesses including the recent acquisitions of LIQUENT, Inc. and HERON Group Ltd., Inc., or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 as filed with the Securities and Exchange Commission (SEC) on May 2, 2014, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.